AbbVievsPuma Biotechnology

ABBV and PBYI stock compared: price, dividend, valuation and results, from SEC filings.

PBYI

Puma Biotechnology Inc

$7.14

Value $363M

+0.00%
PBYI's page

AbbVie (ABBV) has a market value of $509B and Puma Biotechnology (PBYI) $363M. Over the last year, with dividends, ABBV moved +26.7% and PBYI +44.0%. The P/E is 49.5 for ABBV and 15.2 for PBYI. Dividend yield: ABBV 2.40%, PBYI none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$509B

    PBYI$363M

    ABBV is 1,402 times PBYI

  • Revenue, 12 months

    ABBV$66.0B

    PBYI$232M

    ABBV is 285 times PBYI

  • Net income, 12 months

    ABBV$10.3B

    PBYI$24M

    ABBV is 434 times PBYI

  • Operating margin

    ABBV32.2%

    PBYI11.3%

    20.9 points apart

  • ROIC

    ABBV25.7%

    PBYI12.8%

    12.9 points apart

  • P/E

    ABBV49.5

    PBYI15.2

    ABBV is 3.2 times PBYI

  • Dividend yield

    ABBV2.4%

    PBYI0.0%

    2.4 points apart

  • 5-year return

    ABBV+193.3%

    PBYI+103.4%

    89.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+193.3%

PBYI+103.3%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsPBYIWith dividends
1 year since November 17, 2025+26.7%Price +23.0%+44.0%Price +44.0%
3 years since November 17, 2023+130.2%+32.0% a yearPrice +108.2%+85.5%+22.9% a yearPrice +85.5%
5 years since November 17, 2021+193.3%+24.0% a yearPrice +145.3%+103.4%+15.3% a yearPrice +103.4%
10 years since November 18, 2016+615.2%+21.7% a yearPrice +375.7%-83.5%-16.5% a yearPrice -83.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbViePBYIPuma Biotechnology

Valuation

ABBVPBYI
Valuation
Price$288.01$7.14
Market value$509B$363M
Enterprise value (EV)$579B$308M
P/E49.515.2
P/E, 5-year median57.09.6
P/B–2.5
EV/EBIT27.311.8
Free cash flow yield3.7%12.7%

Results and growth

ABBVPBYI
Results and growth
Revenue, 12 months$66.0B$232M
Net income, 12 months$10.3B$24M
Free cash flow, 12 months$18.9B$46M
Earnings per share, 12 months$5.81$0.46
Revenue growth, year on year8.6%-0.9%
Revenue growth a year, past+5.9%over 5 years+0.3%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVPBYI
Margins and returns on capital
Gross margin73.7%73.6%
Operating margin32.2%11.3%
Net margin15.7%10.3%
ROIC25.7%12.8%
ROE–18.1%

Balance sheet

ABBVPBYI
Balance sheet
Cash$10.8B$101M
Total debt$80.9B$50M
Net debt / EBITDA3.2-1.5
Interest cover7.1×12.9×

Dividends and buybacks

ABBVPBYI
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or PBYI

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Puma Biotechnology?

By market value, AbbVie ($509B) is about 1,401.9 times Puma Biotechnology ($363M), at today's prices.

How did ABBV and PBYI stock do over the last 10 years?

Since November 18, 2016, ABBV's price moved +375.7% and PBYI's -83.5%. With dividends: ABBV +615.2% (+21.7% a year), PBYI -83.5% (-16.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or PBYI?

The dividend yield at today's price is 2.40% for AbbVie and none for Puma Biotechnology. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and PBYI?

At today's price, the P/E is 49.5 for ABBV and 15.2 for PBYI. The median of the last five years was 57.0 and 9.6, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Puma Biotechnology?

Over the last twelve months, the net margin was 15.7% for AbbVie and 10.3% for Puma Biotechnology, and the operating margin 32.2% and 11.3%. Revenue was $66.0B and $232M.

Which is the better investment, AbbVie or Puma Biotechnology?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.